{"id":71944,"date":"2023-07-26T13:00:58","date_gmt":"2023-07-26T11:00:58","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=71944"},"modified":"2026-04-08T11:59:08","modified_gmt":"2026-04-08T09:59:08","slug":"veeva-pulse-field-trends-report-1q2q23","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/veeva-pulse-field-trends-report-1q2q23\/","title":{"rendered":"³Ô¹Ï±¬ÁÏ Pulse Field Trends Report"},"content":{"rendered":"<br \/>\n<style>\n  .after-arrow-down-orange, .after-arrow-up-orange {\n    color: #F7981D;\n}\n  .after-arrow-down-orange::after {\n    display: inline-block;\n    content: \"\";\n    font-size: 0;\n    margin-left: 5px;\n    margin-bottom: 1px;\n    width: 0;\n    height: 0;\n    border-style: solid;\n    border-width: 7px 5px 0 5px;\n    border-color: #F7981D transparent transparent transparent;\n}\n.after-arrow-up-orange::after {\n    display: inline-block;\n    content: \"\";\n    font-size: 0;\n    margin-left: 5px;\n    margin-bottom: 1px;\n    width: 0;\n    height: 0;\n    border-style: solid;\n    border-width: 0px 5px 7px 5px;\n    border-color:  transparent transparent #F7981D transparent;\n}\n.after-arrow-down-orange:hover::after {\n    border-color: #e97f16 transparent transparent transparent;\n}\n.after-arrow-up-orange:hover::after {\n    border-color: transparent transparent  #e97f16 transparent;\n}<\/p>\n<p>.after-arrow-down-orange.active,.after-arrow-up-orange.active {\n    color: #FA6D18;\n}\n.after-arrow-down-orange.active::after {\n    border-color: #FA6D18 transparent transparent transparent;\n}\n.after-arrow-up-orange.active::after {\n    border-color: transparent transparent #FA6D18  transparent;\n}<\/p>\n<p>.down-links  {\npadding:12px 0;\ntext-align:center;\nmargin-top:60px;\nmargin-bottom:40px;\n}\n.down-links a {\nfont-size:15px; line-height:21px;\n}\n.down-links div {\ndisplay:inline-block;\npadding:5px 16px;\nwhite-space:nowrap;\n}\n.generic-container h3 {\nfont-weight:500;\nmargin-top:35px;\nmargin-bottom:20px;\n}\np.pulse-sub {\nfont-size:26px;\nline-height:33px;\n}\np.pulse-sub span {\ndisplay:block;\nfont-weight:500;\n}\n.resources-content hr {\nmargin-top: 50px;\nmargin-bottom: 10px;\nborder: 0;\nborder-top: 2px solid #afafaf;\n}\n.resources-content hr.divide {\nmargin-top: 50px;\nmargin-bottom: 40px;\nborder: 0;\nborder-top: 1px solid #ccc;\n}\n.resources-content h2 {\nmargin-bottom:30px;\nfont-weight:500;\nfont-size:30px;\n}\n.resources-content h2.fake-h1 {\nmargin-bottom:30px;\nfont-weight:300;\nfont-size: 38px;\n}\n@media (max-width: 767px) {\n    .resources-content h2.fake-h1 {\nmargin-bottom:25px;\nfont-weight:300;\nfont-size: 30px;\n}\n.resources-content h2 {\nmargin-bottom:25px;\nfont-weight:400;\nfont-size:25px;\n}\np.pulse-sub {\nfont-size:22px;\nline-height:30px;\n}\n.down-links  {\npadding:12px 0;\ntext-align:center;\nmargin-top:40px;\nmargin-bottom:40px;\n}\n}\n@media (max-width: 450px) {\n.down-links div {\ndisplay:block;\npadding:5px 20px;\nwhite-space:nowrap;\n}\n}<\/p>\n<p>@media only screen and (min-width: 768px) and (max-width: 960px) {\n    .down-links div {\n        padding: 5px 10px;\n    }\n    .down-links a {\n        font-size: 12px;\n    }\n}<\/p>\n<p>@media only screen and (min-width: 961px) and (max-width: 996px) {\n    .down-links div {\n        padding: 5px 14px;\n    }\n    .down-links a {\n        font-size: 14px;\n    }\n}\n<\/style>\n<p><!-- \n\n\n<p class=\"resources-sub-title\">MARCH 2023<\/p>\n\n\n --><\/p>\n<h2 class=\"mt-40\">Pre-Launch Field Medical Education Leads to 1.5x Increase in Treatment Adoption<\/h2>\n<h3 class=\"mb-0\">70% of KOLs engage with only one biopharma, as traditional planning misses most experts<\/h3>\n<p>For the first time, the biopharma industry has clear data demonstrating the impact of field medical on clinical practice in a launch setting. A new analysis of migraine products shows that <strong>disease state education by field medical with key opinion leaders (KOLs) before launch is associated with 1.5 times greater treatment adoption<\/strong><sup>1<\/sup> across that healthcare organization (HCO) over the first six months post-launch.<\/p>\n<p>Despite this clear connection between scientific engagement and treatment adoption, new data also shows most KOLs are underserved by field medical. ³Ô¹Ï±¬ÁÏ Pulse data reveals that <strong>70% of KOLs engage with only one biopharma<\/strong>, severely limiting scientific exchange, medical insights, and potential treatment adoption.<\/p>\n<p><strong>The industry lacks a standard, data-driven approach to identifying, prioritizing, and engaging KOLs.<\/strong> But companies like Lundbeck are combining real-time customer intelligence and CRM data to create a new engagement model.<\/p>\n<p>\u201cThe right data is foundational to our engagement strategy. As we prepared for the launch of new treatments, this data- driven approach helped us build the right relationships and focus our resources where they will have the greatest scientific impact,\u201d said Christine Castro, director, medical affairs excellence at Lundbeck.<\/p>\n<p>Ensure your field medical team is creating the impact that matters most with <a href=\"\/eu\/services\/business-consulting-services\/\">³Ô¹Ï±¬ÁÏ Business Consulting\u2019s<\/a> in-depth analysis.<\/p>\n<p>Thank you,<\/p>\n<p><img decoding=\"async\" src=\"\/wp-content\/uploads\/2022\/11\/signature.png\" alt=\"\"><img decoding=\"async\" style=\"border-radius:50%\"  src=\"https:\/\/www.veeva.com\/wp-content\/uploads\/2022\/04\/Headshot-Rizzo.png\" alt=\"\"><br \/>\nDan Rizzo<\/p>\n<p>Global Head of ³Ô¹Ï±¬ÁÏ Business Consulting<\/p>\n<hr class=\"divide\">\n<div style=\"position:relative;\">\n  <a id=\"Insight-1\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2 class=\"mt-40\">Field Medical Has a Significant Impact on Launch Success<\/h2>\n<p>Medical science liaison (MSL) engagement with KOLs before product launch, either in person or via video, results in 1.5 times greater treatment adoption across the HCO within the first six months of launch, compared to HCOs whose KOLs were not engaged.<sup>2<\/sup> This early education by MSLs has a lasting impact, as new treatment starts sustain at 1.3 times greater 18 to 24 months after product launch. These results show what biopharmas have long understood but were not able to accurately measure.<\/p>\n<script>\n\t\t\twindow._wq = window._wq || [];\n\t\t\t_wq.push({\n\t\t\t  id: \"1c6zfju474\",\n\t\t\t  options: {\n\t\t\t\tplugin: {\n\t\t\t\t  \"captions\": {\n\t\t\t\t\tonByDefault: false\n\t\t\t\t  }\n\t\t\t\t}\n\t\t\t  }\n\t\t\t});\n\t\t\t<\/script><script src=\"https:\/\/fast.wistia.com\/embed\/medias\/1c6zfju474.jsonp\" async><\/script><script src=\"https:\/\/fast.wistia.com\/assets\/external\/E-v1.js\" async><\/script><div class=\"wistia_responsive_padding\" style=\"padding:56.25% 0 0 0;position:relative;\"><div class=\"wistia_responsive_wrapper\" style=\"height:100%;left:0;position:absolute;top:0;width:100%;\"><div class=\"wistia_embed wistia_async_1c6zfju474 videoFoam=true\" style=\"height:100%;position:relative;width:100%\"><div class=\"wistia_swatch\" style=\"height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;\"><img decoding=\"async\" src=\"https:\/\/fast.wistia.com\/embed\/medias\/1c6zfju474\/swatch\" style=\"filter:blur(5px);height:100%;object-fit:contain;width:100%;\" alt=\"\" aria-hidden=\"true\" onload=\"this.parentNode.style.opacity=1;\" \/><\/div><\/div><\/div><\/div>\n<p>Despite this impact, ³Ô¹Ï±¬ÁÏ Pulse data shows that investment in medical field force size over the last 12 months has remained flat. HCPs, meanwhile, are overwhelmingly asking for more interactions \u2013 <a href=\"https:\/\/www.bcg.com\/publications\/2021\/pharma-industry-changing-doctor-expectations\" rel=\"noopener noreferrer\" target=\"_blank\">91% of HCPs say visits by medical science liaisons are very effective<\/a> but underused by biopharma.<\/p>\n<div style=\"position:relative;\">\n  <a id=\"Insight-2\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2 class=\"mt-40\">Despite Demand, 70% of KOLs Engage With Only One Biopharma<\/h2>\n<p>MSLs spend significant time with the KOLs they engage. But, while the depth of individual connections may be substantial, the breadth of KOL engagement is not. New ³Ô¹Ï±¬ÁÏ Pulse and ³Ô¹Ï±¬ÁÏ Link data shows that nearly 70% of KOLs only interact with one company\u2019s field medical team.<sup>3<\/sup><\/p>\n<script>\n\t\t\twindow._wq = window._wq || [];\n\t\t\t_wq.push({\n\t\t\t  id: \"th5rvgehdv\",\n\t\t\t  options: {\n\t\t\t\tplugin: {\n\t\t\t\t  \"captions\": {\n\t\t\t\t\tonByDefault: false\n\t\t\t\t  }\n\t\t\t\t}\n\t\t\t  }\n\t\t\t});\n\t\t\t<\/script><script src=\"https:\/\/fast.wistia.com\/embed\/medias\/th5rvgehdv.jsonp\" async><\/script><script src=\"https:\/\/fast.wistia.com\/assets\/external\/E-v1.js\" async><\/script><div class=\"wistia_responsive_padding\" style=\"padding:56.25% 0 0 0;position:relative;\"><div class=\"wistia_responsive_wrapper\" style=\"height:100%;left:0;position:absolute;top:0;width:100%;\"><div class=\"wistia_embed wistia_async_th5rvgehdv videoFoam=true\" style=\"height:100%;position:relative;width:100%\"><div class=\"wistia_swatch\" style=\"height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;\"><img decoding=\"async\" src=\"https:\/\/fast.wistia.com\/embed\/medias\/th5rvgehdv\/swatch\" style=\"filter:blur(5px);height:100%;object-fit:contain;width:100%;\" alt=\"\" aria-hidden=\"true\" onload=\"this.parentNode.style.opacity=1;\" \/><\/div><\/div><\/div><\/div>\n<p class=\"mt-30\">Further, 30% of global experts, as identified in ³Ô¹Ï±¬ÁÏ Link Key People, have no recorded interaction with MSLs at all.<sup>4<\/sup> Whether medical affairs teams miss KOLs in mapping exercises or fail to record interactions, the result is the same \u2013 measuring the impact and connecting it to other insights across the organization is impossible.<\/p>\n<p>The way MSLs select KOLs during planning contributes to this problem:<\/p>\n<ul>\n<li>Selection methods can be highly biased, especially toward traditional experts<\/li>\n<li>Prioritization methods do not reflect true KOL influence<\/li>\n<li>Narrow feedback loops limit medical insights and engagement with a broader scientific audience<\/li>\n<\/ul>\n<div style=\"position:relative;\">\n  <a id=\"Insight-3\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2 class=\"mt-50\">Identify and Prioritize High-Impact KOLs With Industry Data<\/h2>\n<p class=\"mb-20\">Real-time, connected data can broaden access to the right scientific experts as well as generate and share insights across the organization quickly and effectively. By using a data-driven approach, <a href=\"\/eu\/products\/veeva-link\/\">MSLs at one top pharma company improved scientific engagement strategy<\/a> with medical experts:<\/p>\n<script>\n\t\t\twindow._wq = window._wq || [];\n\t\t\t_wq.push({\n\t\t\t  id: \"4ctf7rb976\",\n\t\t\t  options: {\n\t\t\t\tplugin: {\n\t\t\t\t  \"captions\": {\n\t\t\t\t\tonByDefault: false\n\t\t\t\t  }\n\t\t\t\t}\n\t\t\t  }\n\t\t\t});\n\t\t\t<\/script><script src=\"https:\/\/fast.wistia.com\/embed\/medias\/4ctf7rb976.jsonp\" async><\/script><script src=\"https:\/\/fast.wistia.com\/assets\/external\/E-v1.js\" async><\/script><div class=\"wistia_responsive_padding\" style=\"padding:56.25% 0 0 0;position:relative;\"><div class=\"wistia_responsive_wrapper\" style=\"height:100%;left:0;position:absolute;top:0;width:100%;\"><div class=\"wistia_embed wistia_async_4ctf7rb976 videoFoam=true\" style=\"height:100%;position:relative;width:100%\"><div class=\"wistia_swatch\" style=\"height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;\"><img decoding=\"async\" src=\"https:\/\/fast.wistia.com\/embed\/medias\/4ctf7rb976\/swatch\" style=\"filter:blur(5px);height:100%;object-fit:contain;width:100%;\" alt=\"\" aria-hidden=\"true\" onload=\"this.parentNode.style.opacity=1;\" \/><\/div><\/div><\/div><\/div>\n<p class=\"mt-30\">Data alone does little, however. The best strategy ingests new data about KOLs quickly, prioritizes engagement based on KOL influence, and drives medical insights back into the business.<\/p>\n<p>Reach out to <a href=\"\/eu\/services\/business-consulting-services\/\">³Ô¹Ï±¬ÁÏ Business Consulting<\/a> to find out how you can use ³Ô¹Ï±¬ÁÏ Pulse data to identify the right KOLs and improve scientific engagement.<\/p>\n<p><footnotes><br \/>\n   <sup>1, 2<\/sup> U.S.-based analysis of migraine products using data from ³Ô¹Ï±¬ÁÏ Link, ³Ô¹Ï±¬ÁÏ OpenData, ³Ô¹Ï±¬ÁÏ Compass, and ³Ô¹Ï±¬ÁÏ Pulse, March 2019\u2013June 2023.<br \/>\n   <sup>3, 4<\/sup> U.S. ³Ô¹Ï±¬ÁÏ Pulse, ³Ô¹Ï±¬ÁÏ Link Key People data, April 2022\u2013April 2023.<br \/>\n<\/footnotes><\/p>\n<hr class=\"divide\">\n<h2 class=\"fake-h1\">Global and Regional Trends<\/h2>\n<p>This report highlights global and regional field engagement trends from ³Ô¹Ï±¬ÁÏ Pulse data between July 2022 and June 2023. ³Ô¹Ï±¬ÁÏ Pulse data is sourced from ³Ô¹Ï±¬ÁÏ\u2019s aggregated CRM activity dataset, inclusive of field engagement stats from all instances of ³Ô¹Ï±¬ÁÏ CRM globally. For the first time, this report also includes insights into global field medical trends.<\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-down-orange quicklink active\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-down-orange quicklink\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-down-orange quicklink\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-down-orange quicklink\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-down-orange quicklink\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"Global-field\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>Global field medical trends<\/h2>\n<h3 class=\"text-center\">Figure 1: Channel mix evolution, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-1-Channel-Mix-Evolution-Global-Medical.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 2: Channel mix, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-2-Channel-Mix-Global-Medical.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Global field medical activity<\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 3: Activity by region, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-3-Activity-by-Region-Global-Medical.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 4: Activity by company size, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-4-Activity-by-Company-Size-Global-Medical.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Global field medical engagement quality <\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 5: Approved email volume, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-5-Approved-Email-Volume-Global-Medical.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 6: Content usage by channel, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-6-Content-Usage-by-Channel-Global-Medical.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 7: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, global field medical<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-7-Meeting-Duration-Global-Medical.png\" alt=\"\" \/><\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-up-orange quicklink\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-down-orange quicklink active\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-down-orange quicklink\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-down-orange quicklink\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-down-orange quicklink\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"Global\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>Global trends: all field roles<\/h2>\n<h3 class=\"text-center\">Figure 8: Channel mix evolution, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-8-Channel-Mix-Evolution-Global.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 9: Channel mix, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-9-Channel-Mix-Global.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Global field team activity<\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 10: Activity by region, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-10-Activity-by-Region-Global.png\" alt=\"\" \/><\/p>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 11: Activity by user type, global<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-11-Activity-by-User-Type-Global.png\" alt=\"\" \/>\n\t<\/div>\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 12: Activity by company size, global<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-12-Activity-by-Company-Size-Global.png\" alt=\"\" \/>\n\t<\/div>\n<\/div>\n<hr>\n<p class=\"pulse-sub\">\n<span>Global engagement quality<\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 13: Approved email volume, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-13-Approved-Email-Volume-Global.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 14: Content usage by channel, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-14-Content-Usage-by-Channel-Global.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 15: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, global<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-15-Meeting-Duration-Global.png\" alt=\"\" \/><\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-up-orange quicklink\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-up-orange quicklink\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-down-orange quicklink active\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-down-orange quicklink\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-down-orange quicklink\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"US\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>U.S. market trends<\/h2>\n<h3 class=\"text-center\">Figure 16: Channel mix evolution, U.S.<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-16-Channel-Mix-Evolution-US.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 17: Channel mix, U.S.<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-17-Channel-Mix-US.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>U.S. field team activity<\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 18: Activity, U.S.<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-18-Trending-Producitivity-US.png\" alt=\"\" \/><\/p>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 19: Activity by user type, U.S.<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-19-Activity-by-User-Type-US.png\" alt=\"\" \/>\n\t<\/div>\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 20: Activity by company size, U.S.<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-20-Activity-by-Company-Size-US.png\" alt=\"\" \/>\n\t<\/div>\n<\/div>\n<hr>\n<p class=\"pulse-sub\">\n<span>U.S. engagement quality<\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 21: Approved email volume, U.S.<\/h4>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-21-Approved-Email-Volume-US.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 22: Content usage by channel, U.S.<\/h4>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-22-Content-Usage-by-Channel-US.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 23: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, U.S. <\/h4>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-23-Meeting-Duration-US.png\" alt=\"\" \/><\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-up-orange quicklink\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-up-orange quicklink\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-up-orange quicklink\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-down-orange quicklink active\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-down-orange quicklink\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"Europe\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>Europe market trends <\/h2>\n<h3 class=\"text-center\">Figure 24: Channel mix evolution, Europe<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-24-Channel-Mix-Evolution-Europe.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 25: Channel mix, Europe<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-25-Channel-Mix-Global-Europe.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Europe field team activity<\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 26: Activity by country, EU5<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-26-Activity-by-country-EU5.png\" alt=\"\" \/><\/p>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 27: Activity by user type, Europe<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-27-Activity-by-User-Type-Europe.png\" alt=\"\" \/>\n\t<\/div>\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 28: Activity by company size, Europe<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-28-Activity-by-Company-Size-Europe.png\" alt=\"\" \/>\n\t<\/div>\n<\/div>\n<hr>\n<p class=\"pulse-sub\">\n<span>Europe engagement quality<\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 29: Approved email volume, Europe<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-29-Approved-Email-Volume-Europe.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 30: Content usage by channel, Europe<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-30-Content-Usage-by-Channel-Europe.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 31: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, Europe<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-31-Meeting-Duration-Europe.png\" alt=\"\" \/><\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-up-orange quicklink\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-up-orange quicklink\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-up-orange quicklink\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-up-orange quicklink\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-down-orange quicklink active\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"Asia\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>Asia market trends<\/h2>\n<h3 class=\"text-center\">Figure 32: Channel mix evolution, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-32-Channel-Mix-Evolution-APAC.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 33: Channel mix, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-33-Channel-Mix-APAC.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Asia field team activity<\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 34: Activity by country, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-34-Activity-by-Country-Asia-APAC.png\" alt=\"\" \/><\/p>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 35: Activity by user type, Asia<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-35-Activity-by-User-Type-APAC.png\" alt=\"\" \/>\n\t<\/div>\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 36: Activity by company size, Asia<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-36-Activity-by-Company-Size-APAC.png\" alt=\"\" \/>\n\t<\/div>\n<\/div>\n<hr>\n<p class=\"pulse-sub\">\n<span>Asia engagement quality<\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 37: Approved email volume, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-37-Approved-Email-Volume-APAC.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 38: Content usage by channel, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-38-Content-Usage-by-Channel-APAC.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 39: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, Asia<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-39-Meeting-Duration-APAC.png\" alt=\"\" \/><\/p>\n<div class=\"row down-links mt-40\" style=\"background-color:#f4f4f4\">\n<div>\n\t\t<a href=\"#Global-field\" class=\"after-arrow-up-orange quicklink\">Global field medical trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Global\" class=\"after-arrow-up-orange quicklink\">Global trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#US\" class=\"after-arrow-up-orange quicklink\">U.S. trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Europe\" class=\"after-arrow-up-orange quicklink\">Europe trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Asia\" class=\"after-arrow-up-orange quicklink\">Asia trends<\/a>\n\t<\/div>\n<div>\n\t\t<a href=\"#Latam\" class=\"after-arrow-down-orange quicklink active\">Latin America trends<\/a>\n\t<\/div>\n<\/div>\n<div style=\"position:relative;\">\n  <a id=\"Latam\" style=\"position: absolute;top: -200px;\"><\/a>\n<\/div>\n<h2>Latin America market trends<\/h2>\n<h3 class=\"text-center\">Figure 40: Channel mix evolution, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-40-Channel-Mix-Evolution-LATAM.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 41: Channel mix, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-41-Channel-Mix-LATAM.png\" alt=\"\" \/><\/p>\n<hr>\n<p class=\"pulse-sub\">\n<span>Latin America field team activity <\/span><br \/>\nWeekly activity per user by engagement channel\n<\/p>\n<h3 class=\"text-center\">Figure 42: Activity by country, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-42-Activity-by-Country-LATAM.png\" alt=\"\" \/><\/p>\n<div class=\"row\">\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 43: Activity by user type, Latin America<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-43-Activity-by-User-Type-LATAM.png\" alt=\"\" \/>\n\t<\/div>\n<div class=\"col-sm-6\">\n<h3 class=\"text-center\">Figure 44: Activity by company size, Latin America<\/h3>\n<p>\t\t<img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-44-Activity-by-Company-Size-LATAM.png\" alt=\"\" \/>\n\t<\/div>\n<\/div>\n<hr>\n<p class=\"pulse-sub\">\n<span>Latin America engagement quality <\/span><br \/>\nConsolidation of key quality metrics\n<\/p>\n<h3 class=\"text-center\">Figure 45: Approved email volume, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-45-Approved-Email-Volume-LATAM.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 46: Content usage by channel, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-46-Content-Usage-by-Channel-LATAM.png\" alt=\"\" \/><\/p>\n<h3 class=\"text-center\">Figure 47: ³Ô¹Ï±¬ÁÏ CRM Engage meeting duration, Latin America<\/h3>\n<p><img decoding=\"async\" class=\"img-responsive m-auto\" src=\"https:\/\/www.veeva.com\/eu\/wp-content\/uploads\/2023\/07\/Figure-47-Meeting-Duration-LATAM.png\" alt=\"\" \/><\/p>\n<hr class=\"mb-0\" style=\"border-top: 4px solid #444;\">\n<h2 class=\"fake-h1 mt-10\">Appendix: Data dictionary<\/h2>\n<p class=\"pulse-sub\">\n<span>Metric definitions<\/span>\n<\/p>\n<ul>\n<li><strong>Channel mix evolution over time:<\/strong> Weekly ³Ô¹Ï±¬ÁÏ CRM activity volume broken down by the channel of engagement (in-person, phone, video, email, chat, or text)<\/li>\n<li><strong>Channel mix:<\/strong> Total ³Ô¹Ï±¬ÁÏ CRM activity volume broken down by engagement channel percentage<\/li>\n<li><strong>Weekly activities per user:<\/strong> The average weekly number of ³Ô¹Ï±¬ÁÏ CRM activities submitted per number of users active in ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>Approved email volume:<\/strong> Volume of approved emails sent via ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>Email open rate:<\/strong> Percentage of approved emails opened at least once out of all approved emails sent via ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>Email click rate:<\/strong> Percentage of approved emails clicked at least once out of all approved emails sent via ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>In-person % CLM usage:<\/strong> Percentage of in-person engagements that leveraged content in ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>Video % CLM usage:<\/strong> Percentage of video engagements that leveraged content in ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>³Ô¹Ï±¬ÁÏ CRM Engage meeting % CLM usage:<\/strong> Percentage of ³Ô¹Ï±¬ÁÏ CRM Engage meetings that leveraged content in ³Ô¹Ï±¬ÁÏ CRM<\/li>\n<li><strong>³Ô¹Ï±¬ÁÏ CRM Engage meeting duration:<\/strong> The average duration of ³Ô¹Ï±¬ÁÏ CRM Engage meetings in minutes<\/li>\n<\/ul>\n<p class=\"pulse-sub mt-30\">\n<span>Engagement channel definitions<\/span>\n<\/p>\n<ul>\n<li><strong>In-person:<\/strong> Submitted calls with a CRM Standard Metrics call channel value of \u2018in-person\u2019<\/li>\n<li><strong>Phone:<\/strong> Submitted calls with a CRM Standard Metrics call channel value of \u2018phone\u2019<\/li>\n<li><strong>Video:<\/strong> ³Ô¹Ï±¬ÁÏ CRM Engage calls and video calls via other platforms that are then recorded as calls in ³Ô¹Ï±¬ÁÏ CRM with a Standard Metrics call channel value of \u2018video\u2019<\/li>\n<li><strong>Email:<\/strong> Approved emails and emails sent via other platforms that are then recorded as calls in ³Ô¹Ï±¬ÁÏ CRM with a Standard Metrics call channel value of \u2018email\u2019<\/li>\n<li><strong>Chat or text:<\/strong> Submitted calls with a CRM Standard Metrics call channel value of \u2018chat or text\u2019<\/li>\n<\/ul>\n<p class=\"pulse-sub mt-30\">\n<span>User type definitions<\/span>\n<\/p>\n<ul>\n<li><strong>Sales:<\/strong> Users that have been classified with the \u2018sales\u2019 value in the CRM Standard Metrics user type field<\/li>\n<li><strong>Key account manager:<\/strong> Users that have been classified with the \u2018key account manager\u2019 value in the CRM Standard Metrics user type field<\/li>\n<li><strong>Medical:<\/strong> Users that have been classified with the \u2018medical\u2019 value in the CRM Standard Metrics user type field<\/li>\n<li><strong>Top global biopharma:<\/strong> Top 17 global biopharma companies by revenue<\/li>\n<li><strong>Rest of industry:<\/strong> All other biopharmas<\/li>\n<\/ul>\n<p class=\"pulse-sub mt-30\">\n<span>Region definitions<\/span>\n<\/p>\n<ul>\n<li><strong>Global:<\/strong> All markets globally <\/li>\n<li><strong>Europe:<\/strong> Albania, Andorra, Armenia, Aruba, Austria, Azerbaijan, Belarus, Belgium, Bermuda, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, French Polynesia, Georgia, Germany, Greece, Greenland, Guadeloupe, Guernsey, Hungary, Ireland, Italy, Jersey, Latvia, Lithuania, Luxembourg, Macedonia, Malta, Martinique, Republic of Moldova, Monaco, Montenegro, Netherlands, New Caledonia, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom<\/li>\n<li><strong>Asia:<\/strong> Australia, Bangladesh, Bhutan, Brunei Darussalam, Cambodia, Cocos (Keeling) Islands, Indonesia, Japan, Kazakhstan, Republic of Korea, Kyrgyzstan, Malaysia, Mongolia, Myanmar, Nauru, Nepal, New Zealand, Philippines, Samoa, Singapore, Solomon Islands, Sri Lanka, Taiwan, Tajikistan, Thailand, Turkmenistan, Uzbekistan, Vietnam<\/li>\n<li><strong>Latin America:<\/strong> Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Trinidad and Tobago, Uruguay, Venezuela<\/li>\n<\/ul>\n<h2 class=\"fake-h1\">Methodology<\/h2>\n<p>The <a href=\"\/eu\/resources\/veeva-hcp-360-trends-report\/\">³Ô¹Ï±¬ÁÏ HCP 360 Trends Report<\/a> is a quarterly industry benchmark for global and regional healthcare professional (HCP) engagement across the life sciences industry. The report is based on proprietary ³Ô¹Ï±¬ÁÏ Pulse data and insights from field engagement activities of more than 80% of all industry representatives worldwide (Asia Pacific, Europe, Latin America, and the United States). ³Ô¹Ï±¬ÁÏ CRM Standard Metrics \u2014 now used industrywide \u2014 provides the basis for consistent collection and measurement of engagement KPIs including channel mix and productivity across regions, roles, and market segments. The findings are based on:<\/p>\n<ul>\n<li>Approximately 600 million annual global field activities captured in <a href=\"\/eu\/products\/crm-suite\/crm\/\">³Ô¹Ï±¬ÁÏ CRM<\/a> and <a href=\"\/eu\/products\/crm-suite\/engage\/\">³Ô¹Ï±¬ÁÏ CRM Engage<\/a><\/li>\n<li>60 billion prescription (Rx) and medical (Mx) records captured in <a href=\"\/products\/veeva-compass-patient-data\/\">³Ô¹Ï±¬ÁÏ Compass Patient<\/a>, a U.S.-based granular patient data set<\/li>\n<li>3+ million profiles containing publications, clinical trials, conferences, associations, guidelines, grants, payments, social media, news mentions, and influence on community practice from <a href=\"\/eu\/products\/veeva-link\/\">³Ô¹Ï±¬ÁÏ Link Key People<\/a> across 85+ countries and 24 therapeutic areas<\/li>\n<li>Global reference data of healthcare professionals, healthcare organizations, and affiliations from <a href=\"\/eu\/products\/opendata\/\">³Ô¹Ï±¬ÁÏ OpenData<\/a>, containing addresses, emails, specialties, demographics, and compliance data (license information and industry identifiers) available in 65+ countries today and 100+ countries by end of 2023<\/li>\n<\/ul>\n<p>The ³Ô¹Ï±¬ÁÏ Pulse Field Trends Report delivers insights that inform the industry and help field teams align their strategy to key market trends for improved commercial success. The global ³Ô¹Ï±¬ÁÏ Business Consulting team also helps customers inform their strategies using industry benchmarking with ³Ô¹Ï±¬ÁÏ Pulse data.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Field medical education pre-launch has a measurable impact on treatment adoption.<\/p>\n","protected":false},"featured_media":71946,"parent":0,"template":"","class_list":["post-71944","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-html-content-yes","resource-area-20-commercial","resource-area-20-data","resource-area-20-medical","resource-product-20-approved-email","resource-product-20-campaign-manager","resource-product-20-clm","resource-product-20-commercial-content-promomats","resource-product-20-commercial-data-warehouse-nitro","resource-product-20-crm","resource-product-20-medical-crm","resource-product-20-deep-key-account-data-link","resource-product-20-real-time-customer-intelligence-link","resource-product-20-digital-engagement-engage","resource-product-20-events-management","resource-product-20-field-planning-alignments-align-territory-designer","resource-product-20-hcp-access-data","resource-product-20-key-account-management","resource-product-20-network-mdm","resource-product-20-reference-data-opendata-clinical","resource-product-20-customer-reference-data-opendata","resource-type-report"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/71944"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":3,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/71944\/revisions"}],"predecessor-version":[{"id":81539,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/71944\/revisions\/81539"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/71946"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=71944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}